This award recognises a US company that has successfully completed a significant or transformational IPO in the period between 1 September 2017 and 1 September 2018.
Judges paid particular attention to:
Scholar Rock is discovering and developing a pipeline of innovative new medicines to treat a range of serious diseases with high unmet medical need, including neuromuscular disorders, cancer, fibrosis, and anemia.
By focusing on the newly elucidated biology of growth factor activation, Scholar Rock has developed new insights which allow us to selectively target growth factors in the disease microenvironment, to achieve therapeutic effects specifically at the source of disease. Our proprietary technology enables the development of innovative medicines that modulate the supracellular activation of growth factors in order to unlock the vast therapeutic potential of targeting growth factors to treat disease, and deliver new solutions for patients. Our most advanced product candidate, SRK-015, is being developed for the treatment of patients with Spinal Muscular Atrophy (SMA).
Scholar Rock is led by a highly-experienced management team of leaders who have built successful biotechnology companies, and is backed by leading investors.